Tempus ECG-Low EF vs Irregular Rhythm Notification Feature (IRNF)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI Verdict

Tool A is a clinical diagnostic aid for healthcare professionals, analyzing 12-lead ECGs to detect signs of low LVEF within a healthcare facility workflow. Tool B is a consumer-facing screening feature on a wearable device, notifying users of irregular rhythms suggestive of AFib to facilitate discussions with their physicians. While both are FDA-cleared AI tools for cardiac health, their distinct target conditions, deployment models, and intended users make them complementary rather than directly comparable.

Choose Tempus ECG-Low EF if…

Choose Tempus ECG-Low EF if your healthcare facility requires an FDA-cleared AI solution to aid clinicians in identifying patients 40 years or older at risk of heart failure by analyzing standard 12-lead ECG recordings. This tool is best suited for integration into clinical diagnostic workflows to provide a binary output for further evaluation of low left ventricular ejection fraction.

View Tempus ECG-Low EF →

Choose Irregular Rhythm Notification Feature (IRNF) if…

Choose Apple's Irregular Rhythm Notification Feature if you are an individual seeking a proactive, over-the-counter wearable solution to screen for irregular heart rhythms suggestive of AFib in your daily life. This feature empowers users with notifications directly from their Apple Watch, facilitating early discussions with their physicians about potential cardiac concerns.

View Irregular Rhythm Notification Feature (IRNF) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Tempus ECG-Low EF Irregular Rhythm Notification Feature (IRNF)
Pricing Unknown Included with apple watch purchase
Deployment Integrates with current ECG platforms and electronic health records (EHRs). Device-based (Apple Watch), integrated with the iPhone Health app.
FDA Status Cleared AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Irregular Rhythm Notification Feature (IRNF)

Apple's Irregular Rhythm Notification Feature is designed for direct consumer use on a widely adopted device, making it highly accessible and intuitive for patients. Tempus ECG-Low EF, while integrated into clinical workflows for healthcare professionals, lacks a dedicated user interface and operates within existing medical systems, which is less about direct user interaction and more about system-level integration.

Clinical Value

Tempus ECG-Low EF

Tempus ECG-Low EF provides a predictive capability by detecting signs of low LVEF from standard 12-lead ECGs, a condition often requiring echocardiography and a critical precursor to heart failure, offering substantial potential for earlier intervention in a high-burden disease. While Apple IRNF offers valuable screening for AFib, Tempus's tool addresses a more complex diagnostic challenge within a clinical diagnostic setting, aiding clinicians directly in identifying a major chronic condition.

Pricing & Value

Irregular Rhythm Notification Feature (IRNF)

Apple's Irregular Rhythm Notification Feature is included as part of the Apple Watch purchase, making it highly accessible to a vast consumer market without additional direct costs. Tempus ECG-Low EF requires direct vendor contact for pricing, indicating an enterprise-level solution with potentially significant implementation and licensing fees for healthcare facilities.

Enterprise Readiness

Tempus ECG-Low EF

Tempus ECG-Low EF is designed for seamless integration into existing clinical workflows and explicitly offers a Business Associate Agreement (BAA) and HIPAA compliance, which are critical for enterprise adoption in healthcare. Apple's IRNF, as a consumer feature, does not offer a BAA and places HIPAA compliance responsibility on the covered entity for shared data, making it less suitable for direct enterprise-level PHI management.

Innovation

Tempus ECG-Low EF

Tempus ECG-Low EF demonstrates higher innovation by using AI to extract a novel and clinically significant biomarker (low LVEF) from a standard 12-lead ECG, a capability not traditionally available through visual ECG interpretation. This represents a breakthrough in diagnostic capability from existing data, potentially transforming early detection pathways for heart failure.

Support & Docs

Tempus ECG-Low EF

Tempus ECG-Low EF, as an enterprise-grade solution for healthcare facilities, is designed with robust support and documentation for integration into complex clinical workflows and EHR systems. This includes dedicated technical assistance and resources for healthcare professionals, which is more comprehensive than the consumer-focused support and educational materials provided for Apple's Irregular Rhythm Notification Feature.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Tempus ECG-Low EF Irregular Rhythm Notification Feature (IRNF)
Primary Function/Detection Target Detects signs associated with low left ventricular ejection fraction (LVEF u226440%) Screens for irregular heart rhythms suggestive of AFib
Target Patient Population Patients 40 years or older at risk of heart failure Users (Not specified)
Output Type Binary output (Low LVEF Detected / Not Detected) User notifications for detected irregular rhythms
Company Tempus AI Apple

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and Irregular Rhythm Notification Feature (IRNF).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Tempus ECG-Low EF is designed to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. Apple's Irregular Rhythm Notification Feature (IRNF) screens for irregular heart rhythms suggestive of AFib.
Tempus ECG-Low EF is deployed as software integrated into healthcare facility workflows, analyzing 12-lead ECG recordings. The Apple Irregular Rhythm Notification Feature is device-based on the Apple Watch, integrated with the iPhone Health app, providing user notifications for detected rhythms.
Tempus ECG-Low EF analyzes resting, non-ambulatory 12-lead ECG recordings. The Apple Irregular Rhythm Notification Feature analyzes pulse rate data collected by the Apple Watch's photoplethysmograph (PPG) sensor during background heart rhythm checks.
Tempus ECG-Low EF is intended to aid in identifying patients 40+ years at risk of heart failure. The Apple Irregular Rhythm Notification Feature is for Apple Watch users aged 22 and over, empowering them with notifications to facilitate discussions with their physicians regarding irregular rhythms suggestive of AFib.
Tempus ECG-Low EF provides a binary output ('Low LVEF Detected' / 'Not Detected') to aid clinicians in further evaluation, suggesting the need for additional diagnostic workup like an echocardiogram if positive. The Apple Irregular Rhythm Notification Feature provides user notifications if an irregular rhythm suggestive of AFib is identified, which users should discuss with their doctor if they have not been diagnosed with AFib.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.